Myron F. Weiner

Myron F. Weiner

Auto-generated profile, based on publicly available information

Myron F. Weiner

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

67Years (1960-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
HRHeidi C. Rossetti
Heidi C. Rossetti
LLLaura H. Lacritz
Laura H. Lacritz
CCC. Munro Cullum
C. Munro Cullum
MWMyron F. Weiner
Myron F. Weiner
Objective: To provide normative and descriptive data for the Montreal Cognitive Assessment (MoCA) in a large, ethnically diverse sample. Methods: The MoCA was administered to 2,653 ethnically diverse subjects as part of a population-based study of cardiovascular disease (mean age 50.30 years, range 18–85; Caucasian 34%, African American 52%, Hispanic 11%, other 2%). Normative data were generated by age and education. Pearson correlations and analysis of variance were used to examine relationship to demographic variables. Frequency of missed items was also reviewed. Results: Total scores were lower than previously published normative data (mean 23.4, SD 4.0), with 66% falling below the suggested cutoff (<26) for impairment. Most frequently missed items included the cube drawing (59%), delayed free recall (56%; <4/5 words), sentence repetition (55%), placement of clock hands (43%), abstraction items (40%), and verbal fluency (38%; <11 words in 1 minute). Normative data stratified by age and education were derived. Conclusion: These findings highlight the need for population-based norms for the MoCA and use of caution when applying established cut scores, particularly given the high failure rate on certain items. Demographic factors must be considered when interpreting this measure.

15 October 2008 in JAMA
Verified
Journal Article
Open access
PDF file
PAPaul S. Aisen
Paul S. Aisen
LSLon S. Schneider
Lon S. Schneider
MSMary Sano
Mary Sano
RDRamon Diaz-Arrastia
Ramon Diaz-Arrastia
CDChristopher H. van Dyck
Christopher H. van Dyck
LTLeon J. Thal
Leon J. Thal
ContextBlood levels of homocysteine may be increased in Alzheimer disease (AD) and hyperhomocysteinemia may contribute to disease pathophysiology by vascular and direct neurotoxic mechanisms. Even in the absence of vitamin deficiency, homocysteine levels can be reduced by administration of high-dose supplements of folic acid and vitamins B6 and B12. Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline.ObjectiveTo determine the efficacy and safety of B vitamin supplementation in the treatment of AD.Design, Setting, and PatientsA multicenter, randomized, double-blind controlled clinical trial of high-dose folate, vitamin B6, and vitamin B12 supplementation in 409 (of 601 screened) individuals with mild to moderate AD (Mini-Mental State Examination scores between 14 and 26, inclusive) and normal folic acid, vitamin B12, and homocysteine levels. The study was conducted between February 20, 2003, and December 15, 2006, at clinical research sites of the Alzheimer Disease Cooperative Study located throughout the United States.InterventionParticipants were randomly assigned to 2 groups of unequal size to increase enrollment (60% treated with high-dose supplements [5 mg/d of folate, 25 mg/d of vitamin B6, 1 mg/d of vitamin B12] and 40% treated with identical placebo); duration of treatment was 18 months.Main Outcome MeasureChange in the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog).ResultsA total of 340 participants (202 in active treatment group and 138 in placebo group) completed the trial while taking study medication. Although the vitamin supplement regimen was effective in reducing homocysteine levels (mean [SD], −2.42 [3.35] in active treatment group vs −0.86 [2.59] in placebo group; P < .001), it had no beneficial effect on the primary cognitive measure, rate of change in ADAS-cog score during 18 months (0.372 points per month for placebo group vs 0.401 points per month for active treatment group, P = .52; 95% confidence interval of rate difference, −0.06 to 0.12; based on the intention-to-treat generalized estimating equations model), or on any secondary measures. A higher quantity of adverse events involving depression was observed in the group treated with vitamin supplements.ConclusionThis regimen of high-dose B vitamin supplements does not slow cognitive decline in individuals with mild to moderate AD.Trial Registrationclinicaltrials.gov Identifier: NCT00056225

12 July 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
MCM. J. Chandler
M. J. Chandler
LLL. H. Lacritz
L. H. Lacritz
LHL. S. Hynan
L. S. Hynan
HBH. D. Barnard
H. D. Barnard
GAG. Allen
G. Allen
CCC. M. Cullum
C. M. Cullum
Objective: To develop a total or composite score for the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological battery. Method: CERAD total scores were obtained by summing scores from the individual CERAD subtests (excluding the Mini-Mental State Examination [MMSE]) into a total composite (maximum score = 100). The method of tabulating the total score was constructed using normal controls (NCs; n = 424) and patients with AD (n = 835) from the CERAD registry database. The utility of the total score was further tested in independent samples of mild AD (n = 95), mild cognitive impairment (MCI; n = 60), and NC (n = 95) subjects. Results: The CERAD total score was highly accurate in differentiating NC and AD subjects in the CERAD registry. Age, gender, and education effects were observed, and demographic correction scores were derived through multiple regression analysis. Demographically corrected CERAD total scores showed excellent test-retest reliability across samples (r = 0.95) and were highly correlated with the MMSE (r = 0.89) and Clinical Dementia Rating Scale (r = −0.83) in mixed AD and NC samples and with the Blessed Dementia Rating Scale in an AD sample (r = −0.40). The CERAD total score was highly accurate in differentiating independent samples of NC, MCI, and AD subjects. Conclusion: Results provide support for the validity of a Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) total score that can be used along with the normative data to provide an index of overall level of cognitive functioning from the CERAD neuropsychological battery.

1 October 2007 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
GAGreg Allen
Greg Allen
HBHolly Barnard
Holly Barnard
RMRoderick McColl
Roderick McColl
AHAndrea L. Hester
Andrea L. Hester
JFJulie A. Fields
Julie A. Fields
CCC. Munro Cullum
C. Munro Cullum
Alzheimer disease (AD) is the most common type of dementia,1,2 characterized by memory impairment progressing to globally impaired cognition.3 As the human lifespan has increased, so too has the prevalence of AD and widespread concern about this disease, encouraging the search for new modes of early identification and intervention. Recently, neuroimaging techniques have proved to be useful disease-monitoring tools,4,5 prompting further research into their utility for early detection.

26 January 2005 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
SBScott R. Beach
Scott R. Beach
RSRichard Schulz
Richard Schulz
GWGail M. Williamson
Gail M. Williamson
LML. Stephen Miller
L. Stephen Miller
MWMyron F. Weiner
Myron F. Weiner
CLCharles E. Lance
Charles E. Lance

14 November 2000 in Neurology
Verified
Journal Article
Closed access
PDF file
LTL. Teri
L. Teri
RLR.G. Logsdon
R.G. Logsdon
EPE. Peskind
E. Peskind
MRM. Raskind
M. Raskind
MWM.F. Weiner
M.F. Weiner
LTL.J. Thal
L.J. Thal
Background: Treatment of agitation is a crucial problem in the care of patients with AD. Although antipsychotic and antidepressant medications and behavior management techniques (BMT) have each been used to treat agitation, clinical trials of these treatments have been characterized by small sample sizes and uncontrolled treatment designs. Objective: To compare haloperidol, trazodone, and BMT with placebo in the treatment of agitation in AD outpatients. Methods: A total of 149 patients with AD and their caregivers participated in a randomized, placebo-controlled, multicenter trial. Blind assessment was conducted at baseline and after 16 weeks of treatment. The three active treatments were haloperidol, trazodone, and BMT. The Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change was the primary outcome measure. Secondary outcomes included patient agitation, cognition, and function, and caregiver burden. Results: Thirty-four percent of subjects improved relative to baseline. No significant differences on outcome were obtained between haloperidol (mean dose, 1.8 mg/d), trazodone (mean dose, 200 mg/d), BMT, or placebo. Significantly fewer adverse events of bradykinesia and parkinsonian gait were evident in the BMT arm. No other significant difference in adverse events was seen. Symptoms did not respond differentially to the different treatments. Conclusions: Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT, and placebo. More effective pharmacologic, nonpharmacologic, and combination treatments are needed.